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564Objective: Under the Freedom of Information Act, we obtained the follow-up data of the National Emphysema
Treatment Trial (NETT) to determine the long-term outcome for ‘‘a heterogeneous distribution of emphysema
with upper lobe predominance,’’ postulated by the NETT hypothesis to be optimal candidates for lung volume
reduction surgery.
Methods: Using the NETT database, we identified patients with heterogeneous distribution of emphysema with
upper lobe predominance and analyzed for the first time follow-up data for those receiving lung volume reduction
surgery and those receiving medical management. Furthermore, we compared the results of the NETT reduction
surgery group with a previously reported consecutive case series of 250 patients undergoing bilateral lung volume
reduction surgery using similar selection criteria.
Results: Of the 1218 patients enrolled, 511 (42%) conformed to the NETT hypothesis selection criteria and
received the randomly assigned surgical or medical treatment (surgical ¼ 261; medical ¼ 250). Lung volume
reduction surgery resulted in a 5-year survival benefit (70% vs 60%; P ¼ .02). Results at 3 years compared
with baseline data favored surgical reduction in terms of residual volume reduction (25% vs 2%; P<.001), Uni-
versity of California San Diego dyspnea score (16 vs 0 points; P< .001), and improved St George Respiratory
Questionnaire quality of life score (12 points vs 0 points; P< .001). For the 513 patients with a homogeneous
pattern of emphysema randomized to surgical or medical treatment, lung volume reduction surgery produced
no survival advantage and very limited functional benefit.
Conclusions: Patients most likely to benefit from lung volume reduction surgery have heterogeneously distrib-
uted emphysema involving the upper lung zones predominantly. Such patients in the NETT trial had results nearly
identical to those previously reported in a nonrandomized series of similar patients undergoing lung volume
reduction surgery. (J Thorac Cardiovasc Surg 2010;140:564-72)Lung volume reduction surgery (LVRS) is a palliative pro-
cedure for selected patients with severe emphysema whose
respiratory mechanics are severely impaired owing to hyper-
inflation of the lungs and thorax. The goal of LVRS is the
reduction of hyperinflation by removal of the most destroyed
portions of the lung, thus improving respiratory mechanics,
dyspnea, exercise tolerance, and quality of life. The concept
of lung volume reduction was introduced by Brantigan, Mu-
eller, and Kress1 in 1959. Their procedure resulted in a high
operative mortality, and although many of their patients re-
ported clinical improvement, the lack of objective documen-
tation led to skepticism as to the value of the procedure.e Division of Thoracic Surgery, Department of Surgery, University of Penn-
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The Journal of Thoracic and Cardiovascular SurgLVRS was reintroduced in 1995.2 Results from 250 con-
secutive patients undergoing bilateral LVRS were subse-
quently reported3 and demonstrated significant objective
and subjective benefit. Other reports followed and confirmed
the benefit of LVRS.4-9
The reintroduction of LVRS and the documented func-
tional benefit achieved2 attracted a great deal of interest in
the medical and surgical community. However, the rapid
dissemination of the LVRS procedure raised serious ques-
tions regarding its value and its appropriate application.
Patient selection, surgical approach, and technique were
variable as were morbidity, mortality, and reported out-
comes. Data analyzed from Medicare claims with the
LVRS billing codes showed a high mortality rate and signif-
icant postoperative, short-term, and long term hospitaliza-
tions for these patients.4 For these reasons the Health
Care Finance Administration suspended payment for the
procedure and, together with the National Heart, Lung,
and Blood Institute and the Agency for Healthcare Policy
and Research, conducted a prospective randomized clinical
trial of bilateral LVRS known as the National Emphysema
Treatment Trial (NETT). The rationale and design of
the NETT have been reported in detail.10 Screening of pro-
spective patients began in October 1997, and randomizationery c September 2010
Abbreviations and Acronyms
FEV1 ¼ forced expiratory volume in 1 second
LVRS ¼ lung volume reduction surgery
NETT ¼ National Emphysema Treatment Trial
RV ¼ residual volume
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1998.
In 2001 the NETT research group published a preliminary
report identifying a subgroup of NETT patients at high risk
of death after LVRS,11 and such patients were no longer con-
sidered eligible for the trial. Patient entry for the trial ended
in July 2002, at which time a total of 1218 patients had been
randomly assigned to undergo either LVRS or medical man-
agement. The initial NETT report on the early outcome of
the overall study was published in May 2003.12 Long-term
follow-up of the NETT trial, with a median follow-up of
4.3 years, was reported in 2006.13
Under the Freedom of Information Act, we have obtained
and analyzed the NETT data set released as of May 2006.
Using those data, we have specifically analyzed for the first
time the outcome of the medical and surgical patients who
met the original NETT study hypothesis criteria (which we
refer to as the target group), as well as other subgroups who
did not. We further compared the results of these patients
from the NETT study with results we previously reported
in 250 consecutive patients whose selection criteria closely
matched those of the patients who met the NETT hypothesis.METHODS
After institutional review board approval and signature of a data distribu-
tion agreement between the University of Pennsylvania and the National
Heart, Lung, and Blood Institute, we received an electronic data set entitled
‘‘Limited Access Database Documentation’’ containing patient data up to
May 2006. This extensive database consisted of 286 pages documenting
the data fields collected for each patient under the NETT protocol. This elec-
tronic data set was then analyzed with the SPSS 17.0 statistical software
package (SPSS, Inc, Chicago, Ill).
A total of 1218 patients were enrolled in the NETT trial. After a 6- to 10-
week period of pulmonary rehabilitation, patients were then randomized to
either medical therapy or medical therapy plus bilateral LVRS. The median
time from randomization to surgery was 10 days, with 88% of patients as-
signed to LVRS undergoing the procedure within 14 days.
During the development of the NETT protocol, an analysis of available
LVRS data was undertaken, much provided by the NETT centers, to help
guide the study protocols. This generated a hypothesis by the NETT steering
committee as follows: ‘‘Patients who improve (after LVRS) will have
preoperative (A) significant loss of lung elastic recoil (ie, emphysema)
and (B) heterogeneously distributed emphysema involving the upper lung
zones predominantly.’’14
The ultimate inclusion criteria for the NETT trial, however, were not lim-
ited to only such patients. The final selection criteria were ‘‘formulated to
include patients with a diverse distribution of emphysema to examine the
effect of the anatomic distribution of disease on the response to therapy.’’10
We identified the subgroup of patients who met the NETT hypothesis in
the following manner. In the NETT trial, the overall pattern of craniocaudalThe Journal of Thoracic and Cadistribution of emphysema (predominance criteria) was determined by a ra-
diologist who had been trained in the study protocol. On the basis of a chest
computed tomographic scan, the radiologist recorded the pattern of emphy-
sema as belonging to 1 of the following unique categories:
 Upper lobe predominant
 Lower lobe predominant
 Superior segments of lower lobes predominantly
 Diffuse
We used this data field to identify patients who had upper lobe predom-
inant disease.
To identify which patients met the definition of a heterogeneous pattern
of emphysema, the NETT radiologist divided each lung into 3 apical-
to-basal zones, and the severity of emphysema in each zone was scored
visually on a scale of 0 to 4 with a grade of 0 indicating no emphysema
and a grade of 4 indicating the presence of emphysema in more than
75% of the lung zone. Heterogeneous emphysema was defined by the
NETT as a difference in the severity score of at least 2 integers between
any 2 zones in at least 1 lung. Otherwise, the distribution of emphysema
was classified as diffuse (homogenous).
Patients who met the NETT hypothesis were those who met both the
NETT criteria for heterogeneously distributed emphysema and the NETT
criteria for upper lobe predominant disease. It should be noted that under
the NETT definitions, a patient could be classified as both upper lobe pre-
dominant and homogeneous if he or she met the criteria for upper lobe pre-
dominance, but if the severity of the upper lobe emphysema on either side
was not scored greater than 1 integer higher than the other 2 lung zones on
the basis of the severity scoring.
Statistical Analysis
All statistical analysis of NETT patients was based on patients who re-
ceived the assigned treatment. Descriptive statistics are expressed as
mean  SD unless otherwise specified. Categorical data are expressed as
counts and proportions. Comparisons were done with paired, 2-tailed t tests
for means of normally distributed continuous variables and Wilcoxon rank
sum tests for skewed data. Either c2 or Fisher’s exact tests were used to an-
alyze differences among the categorical data. Kaplan–Meier estimation was
used to predict survival.RESULTS
Between January 1998 and July 2002, 1218 patients were
randomized in the NETT trial. Of the 608 patients assigned
to the surgical group, 571 received bilateral LVRS. Of the
610 patients assigned to medical therapy, 566 patients re-
ceived the assigned therapy. Applying the NETT criteria
for the radiographic pattern and distribution of emphysema,
261 of the patients receiving bilateral LVRS corresponded to
the target group (heterogeneous upper lobe predominant dis-
ease) whereas 257 had diffuse disease and 53 had a pattern of
heterogeneous lower lobe predominance. For the medical
group, 250 patients met the target group criteria whereas
256 had diffuse disease and 60 had a pattern of heteroge-
neous lower lobe predominance.Patients With Heterogeneous Upper Lobe
Predominance
For the 261 LVRS patients in this group the mean age was
65.3 years, and for the medical group the mean age was 66.5
years. The median follow-up was 4.3 years.rdiovascular Surgery c Volume 140, Number 3 565
FIGURE 1. Kaplan–Meier survival curves on the treated patients. A, Heterogeneous upper lobe predominant group: LVRS versus medical management,
P ¼ .02. B, Homogeneous NETT LVRS versus medical management, P ¼ .49.
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13 (5%) patients for the surgical group and 4 (1.6%) pa-
tients for the medical group. Figure 1 shows the overall sur-
vival for the 2 groups. Survival at 3 years was 81% for the
surgical group and 74% for the medical group (P¼ .05). At
5 years survival was 70% for the surgical group and 60%
for the medical group (P ¼ .02).
The 2 primary outcome measures chosen by the NETT
trial were survival and maximum exercise capacity mea-
sured in terms of watts. Secondary measures were quality
of life and related disease-specific symptoms. Other out-TABLE 1. Surgery versus medical therapy: Bilateral LVRS in heterogene
Preop:
Surg ¼ 261
MT ¼ 250
Six months
Surg ¼ 224
MT ¼ 183
FEV1 (mean  SD [L],% predicted)
Surgery 0.7  0.2 (26%) 1.0  0.4 (37%
MT 0.7  0.2 (26%) 0.7  0.2 (26%
RV (mean  SD (L),% predicted)
Surgery 5.0  1.0 (226%) 3.4  1.0 (157
MT 5.0  1.0 (227%) 5.0  1.0 (227
UCSD (mean  SD)
Surgery 65  19 41  23z
MT 66  19 65  21
St George (mean  SD)
Surgery 56  13 39  16z
MT 57  13 55  14
Workload (watts, mean  SD)
Surgery 36  22 48  22z
MT 35  20 37  23
Six-minute walk (feet, mean  SD)
Surgery 1166  317 1354  304z
MT 1120  298 1165  311
Surg, Surgery; MT, Medical therapy; FEV1, forced expiratory volume in 1 second; SD, stand
ness of Breath Questionnaire is a 24-item questionnaire about dyspnea. Total score ranges fro
Questionnaire is a 51-item questionnaire on the health-related quality of life with regard to
health-related quality of life. *P .05 for paired comparison with MT scores at same follow
paired comparison with MT scores at same follow-up. {Six-minute walk data available up
566 The Journal of Thoracic and Cardiovascular Surgcome measures were pulmonary function and gas exchange,
oxygen requirement, and 6-minute walk distance.
Table 1 shows selected pulmonary function studies, exer-
cise tolerance, and quality of life assessment for the target
group patients in the surgical and medical groups. The
NETT trial achieved excellent balance between the 2 groups
in terms of baseline parameters. At all postoperative time pe-
riods, the surgical group showed highly significant benefit
compared with medical treatment in terms of forced expira-
tory volume in 1 second (FEV1), residual volume (RV),
dyspnea score, and quality of life. The same was true forous upper lobe predominant group
: One year:
Surg ¼ 199
MT ¼ 153
Two years:
Surg ¼ 167
MT ¼ 121
Three years:
Surg ¼ 116
MT ¼ 72
)z 1.0  0.3 (36%)z 1.0  0.3 (36%)z 0.9  0.3 (33%)*
) 0.8  0.3 (27%) 0.8  0.3 (27%) 0.8  0.3 (27%)
%)z 3.6  1.0 (163%)z 3.6  1.0 (160%)z 3.7  1.0 (163%)z
%) 5.0  1.0 (227%) 5.0  1.0 (227%) 4.9  1.0 (211%)
42  23z 46  24z 49  26z
66  20 67  22 66  22
39  18z 42  17z 44  18z
57  14 56  14 57  15
49  23z 49  24y 43  23
38  24 40  24 38  25
1339  329z 1272  302z {
1128  343 1136  350 {
ard deviation; RV, residual volume; UCSD, University of California San Diego, Short-
m 1 to 120. Lower scores indicate less shortness of breath. The St George’s Respiratory
respiratory symptoms. Total score ranges from 0 to 100. Lower score indicate better
-up. yP .002 for paired comparison with MT scores at same follow-up. zP .001 for
to 24 months.
ery c September 2010
Sanchez et al General Thoracic Surgerymaximum workload with the exception of the 3-year data, at
which time the difference between the LVRS group and the
medical group did not achieve statistical significance but fa-
vored the LVRS group.
After LVRS, improvement in FEV1 over baseline values
was 42%, 35%, and 26% at 6 months, 1 year, and 3 years,
respectively. The decrease in RV was 30%, 28%, and 25%
at the same time periods. For LVRS patients the workload
improved by 34%, 33%, and 18% at 6 months, 1 year,
and 3 years, respectively.
Dyspnea and health-related quality of life as measured by
the St George Respiratory Questionnaire both showed sig-
nificant benefit for LVRS throughout the initial 3-year
follow-up period.G
T
SBilateral LVRS for Upper Lobe Heterogeneous
NETT Group Compared With Previous Consecutive
Case Series
Ciccone and associates3 previously reported results in 250
consecutive patients undergoing bilateral LVRS between
January 1993 and June 2000. All patients had heteroge-
neously distributed emphysema, of whom 229 (92%) had
upper lobe predominance and the remaining 8% had lower
lobe predominance. The mean age was 62  8 years.
Follow-up ranged from 1.8 to 9.1 years, with a median of
4.4 years. One patient was lost to follow-up. More than
95% of evaluable patients had objective pulmonary function
data collected at each follow-up time point out to 5 years
postoperatively.
Figure 2, A, depicts the Kaplan–Meier survival curve for
the 261 NETT LVRS target group compared with the 250 pa-
tients in the Ciccone report.3 Table 2 shows results in terms of
FEV1, RV, and 6-minute walk test for these same patients. It
will be noted that the baseline RV in the case series group was
higher than in the NETT group (5.8  1.3 L vs 5.0  1 L).
However, the baseline values for FEV1 and 6-minute walk
test are virtually identical for the 2 groups. Figure 2, B, de-
picts the post-LVRS change in the FEV1 in the 2 groups.
The reduction in RV after LVRS at 6 months, 1 year, and 3
years was 31% versus 31%, 29% versus 27%, and 28%TABLE 2. Comparisons Ciccone and associates3 and NETT data for LVR
Preop: Ciccone
et al: 250 NETT: 261
Six m
et al:
FEV1 (mean  SD (L),% predicted)
Ciccone et al 0.7  0.3 (26%) 1.1
NETT 0.7  0.2 (26%) 1.0
RV (mean  SD (L),% predicted)
Ciccone et al 5.8  1.3 (277%) 4.0
NETT 5.0  1.0 (226%) 3.4
Six-minute walk (feet, mean  SD)
Ciccone et al 1142  291 1345
NETT 1166  317 1354
Ciccone et al had 8% of heterogeneous non–upper lobe predominant cases. *Six-minute w
The Journal of Thoracic and Caversus 24% for the Ciccone series3 and the NETT series,
respectively.LVRS ComparedWith Medical Treatment for NETT
Patients With Homogeneous Emphysema
Distribution
We compared the results of bilateral LVRS versus medi-
cal therapy for the 518 NETT patients having a homogeneous
pattern of emphysema. A total of 257 patients were random-
ized to LVRS and 261 patients to medical therapy. Figure 1
depicts the survival curve for the 2 groups. It is apparent that
survival is similar for the 2 groups at 5 years. Table 3 com-
pares pulmonary function, dyspnea, quality of life, and max-
imal workload for the 2 groups. Although some measures
show statistically significant benefit in favor of LVRS at 3
years, it is apparent that the magnitude of benefit is consid-
erably diminished compared with the benefit of LVRS
for patients with heterogeneous upper lobe predominant
disease, shown in Table 1.Limitations of NETTAnalysis
The NETT survival data were complete out to 5 years, but
there was significant lack of follow-up data for other param-
eters, which limited our analysis after year 3 of follow-up.
We defined missing data at each time point as a lack of
data for patients known to be alive at the time (1 year, 2
year, etc). For maximum workload, 1 of the 2 primary end
points of the trial, and for pulmonary function studies, data
were missing at 1 year, 2 years, and 3 years for 13%, 21%,
and 36% of the LVRS patients, respectively, and for 30%,
35%, and 43% of the medical patients, respectively.DISCUSSION
The NETT trial represents the only randomized clinical
trial of LVRS with a significant number of patients and
well-defined outcome measures. Just as the LVRS procedure
itself generated considerable controversy, so too did the
methodology, selection process, and reporting of results of
the NETT trial. Among the factors contributing to the con-
troversy were changes in the selection criteria in the midstS
onths: Ciccone
231 NETT: 224
One year: Ciccone
et al: 225 NETT: 199
Three years: Ciccone
et al: 178 NETT: 116
 0.5 (39%) 1.0  0.5 (38%) 0.9  0.5 (34%)
 0.4 (37%) 1.0  0.3 (35%) 0.9  0.3 (33%)
 1.2 (189%) 4.1  1.3 (193%) 4.2  1.3 (198%)
 1.0 (157%) 3.6  1.0 (163%) 3.7  1.0 (163%)
 316 1341  310 1271  305
 304 1339  329 *
alk: data available up to 24 months.
rdiovascular Surgery c Volume 140, Number 3 567
FIGURE2. Results following bilateral LVRS, NETT heterogeneous upper
lobe predominant versus Ciccone and associates.3 A, Kaplan Meier sur-
vival. B, FEV1% predicted. NETT, National Emphysema Treatment Trial;
LVRS, lung volume reduction surgery; FEV1, forced expiratory volume in 1
second.
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relating to patients at high risk of death after the procedure,
and a complex statistical presentation of outcome results in
a manner difficult to interpret and to compare with other
reported series.
Release of the long-term follow-up data of the NETT trial
provided the opportunity to analyze the data in a manner
consistent with previous reports and to clarify and reanalyze
data subsets in a manner that allowed more valid comparison
with other series, and in keeping with the hypothesis of the
NETT trial.
As previously noted, the NETT protocol defined 2 sepa-
rate methods of defining the pattern and severity of emphy-
sema in the lungs. The first was based on which part of the
lung was most affected (‘‘predominance’’) and the second,
based on the 0 to 4 severity score, yielded a classification
of either heterogeneous or homogenous. Thus some patients
assigned to the upper lobe predominance group were classi-
fied as heterogeneous and others were classified as homoge-568 The Journal of Thoracic and Cardiovascular Surgneous. This contributed to the confusion in interpreting the
data presented in the NETT publications. In the initial publi-
cation, ‘‘Patients at High Risk of Death after Lung-Volume-
Reduction Surgery,’’ patient subsets were classified only as
having either a homogenous or a heterogeneous pattern of
emphysema.11 Moreover, most of the patients reported in
that publication were in fact ineligible under the original
NETT selection criteria and were enrolled only after these
criteria were significantly changed in the midst of the trial.
For the reporting of the NETT outcome as a whole,12 pa-
tients were classified as having either upper lobe predomi-
nance or non–upper lobe predominance. Neither of the
initial 2 NETT publications reported results on the subset
of patients who met NETT hypothesis criteria.
Applying the NETT hypothesis to the NETT data reported
to date reveals that only 46% of the 508 patients who re-
ceived bilateral LVRS met the hypothesis selection criteria,
and results in this group demonstrate better outcomes than
any group reported by the NETT to date, in terms of lung
function, exercise tolerance, quality of life, and survival. Fur-
thermore, only this ‘‘target’’ group of patients, as identified
in this article, can be considered to be a group prospectively
identified before initiating the trial, as all other subgroups
reported were retrospectively defined.
Our original and ongoing presumption as to the most ap-
propriate candidates for bilateral LVRS has been that such
candidates should have a heterogeneous pattern of emphy-
sema to provide ‘‘target’’ areas that can be excised with as
little loss of functioning lung as possible. Our report of the
initial 250 consecutive patients undergoing bilateral LVRS
highlights the fact that the vast majority (92%) of patients
with a heterogeneous pattern of emphysema who were
deemed suitable for bilateral LVRS have upper lobe pre-
dominant disease.
The opportunity to compare the results of our previously
reported consecutive case series with similar patients in a ran-
domized trial having similar characteristics was extremely
valuable. The 261 patients in the NETT group had a median
follow-up of 4.3 years compared with a median of 4.4 years
in the consecutive case series. The baseline FEV1 and 6-min-
ute walk distance for the 2 groups were identical. The base-
line RV for the case series (5.8  1.3 L) was somewhat
higher than the NETT group (5.0  1 L), indicating perhaps
more stringent selection criteria in the case series. As the
NETT patients were by definition Medicare patients, the av-
erage age of the NETT group (66.5 years) was somewhat
older than that of the case series (62 years). The results in
the 2 series, however, are virtually identical with respect to
survival curves, improvement in FEV1, and reduction in
RV. This comparison demonstrates that the multicenter
NETT trial was able to achieve very similar results to those
achieved in similar patients in a single-center study. It might
be concluded, therefore, that the results of the multicenter,
randomized NETT trial confirmed the results obtained withery c September 2010
TABLE 3. Surgery versus medical therapy: Bilateral LVRS in homogeneous group
Preop:
Surg ¼ 257
MT ¼ 256
Six months:
Surg ¼ 211
MT ¼ 185
One year:
Surg ¼ 170
MT ¼ 153
Two years:
Surg ¼ 142
MT ¼ 118
Three years:
Surg ¼ 82
MT ¼ 67
FEV1 (mean  SD (L),% predicted)
Surg Homog 0.8  0.2 (27%) 0.9  0.3 (33%)z 0.8  0.3 (32%) 0.8  0.2 (30%) 0.8  0.4 (29%)
MT Homog 0.8  0.2 (27%) 0.8  0.2 (27%) 0.8  0.2 (26%) 0.8  0.3 (27%) 0.7  0.3 (26%)
RV (mean  SD (L),% predicted)
Surg Homog 4.9  1.0 (222%) 3.8  1.0 (172%)z 3.9  1.1 (176%)z 4.0  1.1 (179%)z 4.2  1.3 (187%)y
MT Homog 5.0  1.3 (226%) 4.9  1.2 (219%) 4.9  1.3 (217%) 4.9  1.3 (214%) 4.8  1.1 (210%)
UCSD (mean  SD)
Surg Homog 65  19 49  23z 47  23z 52  23z 52  24z
MT Homog 68  18 67  20 68  19 68  20 69  21
St George (mean  SD)
Surg Homog 65  19z 49  23z 47  23z 52  23* 52  24
MT Homog 58  13 56  14 57  13 57  14 57  14
Workload (watts, mean  SD)
Surg Homog 35  21 43  21 42  22 41  22 38  24
MT Homog 35  21 39  22 38  23 36  22 36  21
Surg, Surgery; Homog, homogenous; MT, medical therapy; FEV1, forced expiratory volume in 1 second; SD, standard deviation; RV, residual volume; UCSD, University of Cal-
ifornia San Diego, Shortness of Breath Questionnaire is a 24-item questionnaire about dyspnea. Total score ranges from 1 to 120. Lower scores indicate less shortness of breath. The
St George’s Respiratory Questionnaire is a 51-item questionnaire on the health-related quality of life with regard to respiratory symptoms. Total score ranges from 0 to 100. Lower
score indicates better health-related quality of life. *P  .05 for paired comparison with MT scores at same follow-up. yP  .002 for paired comparison with MT scores at same
follow-up. zP  .001 for paired comparison with MT scores at same follow-up.
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might be concluded that the results obtained in the case se-
ries, in which follow-up data were far more complete than
in the multicenter trial, confirmed the validity of the random-
ized trial despite considerable missing data. The most impor-
tant additional value obtained from the randomized nature of
the NETT trial is the marked benefit of bilateral LVRS in
well-selected patients when compared with the medical con-
trol group consisting of similar patients.
A second benefit of this report is the opportunity to refine
appropriate selection criteria for LVRS candidates. The
NETT trial included 513 patients with homogeneous dis-
ease, of whom 257 received LVRS and 256 received medi-
cal management. For these patients, surgery was associated
with a 10% operative mortality, offered no apparent long-
term survival benefit, and resulted in less objective and
subjective benefit than observed in the NETT patients with
heterogeneous upper lobe predominant disease. However,
further analysis and further experience with other subgroups
of patients enrolled in the NETT trial might demonstrate
benefit from bilateral LVRS or that the application of
a unilateral procedure for some of these patients might be ap-
propriate. Reports of highly selected patients with a homoge-
neous morphology and patients undergoing unilateral LVRS
have certainly suggested potential benefit.
One of the most controversial aspects of the NETT trial
was the manner in which the data were analyzed and re-
ported, a method quite dissimilar from the methods usually
used when analyzing the results of surgical procedures.
The methodology used to describe statistical differences
between the surgical and medical groups compared theThe Journal of Thoracic and Caprobability of each group achieving a specified target at dif-
ferent periods of time. Data were presented with complex
histograms, and the magnitude of benefit achieved by
patients at each of the chosen time periods was difficult to
describe in simple terms. This is illustrated with the NETT
analysis of the maximum workload achieved, which was
1 of the 2 primary end points of the NETT trial. Workload,
as determined by cycle ergometry, was measured in watts
and statistical analysis between treatment groups determined
whether or not one group or the other was more likely to
achieve a 10-watt improvement over baseline. However,
as noted in the NETT report, there are differences between
men and women in baseline exercise capacity. Thus, to
achieve the target of a 10-watt increase, women would
have to show a 40% improvement whereas men only
a 25% improvement. In the NETT report13 (Table 3), the
2-year results in terms of improvement in exercise capacity
shows that 21% of patients with upper lobe predominant
disease achieved a 10-watt or higher increment in exercise
tolerance whereas only 2% of the medical group achieved
this magnitude of benefit. By comparison, our analysis
(see Table 1) demonstrates that for the ‘‘target’’ LVRS
group, the mean increase over baseline in maximum work-
load was 33% at 6 months, 36% at 1 year, and 36% at
2 years. We believe that this type of data presentation is
more easily interpreted and more easily explained when
describing the benefits of LVRS to physicians and patients.
Much of the controversy surrounding the previously pub-
lished conclusions of the NETT trial is due, at least in part, to
the fact that less than half of the patients enrolled in the trial
met the eligibility criteria consistent with the NETTrdiovascular Surgery c Volume 140, Number 3 569
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Shypothesis as to who would likely benefit from LVRS, but
there was no stratification or separate analysis of this
prospectively identified group of patients. We hope that this
report, using the valuable repository of data collected by the
NETT trial, will help clarify the role of LVRS for selected
patients with emphysema. This is particularly important
inasmuch as none of the endoscopic procedures proposed in
an attempt to achieve a ‘‘volume reduction’’ effect (valves,
installation of adhesives, airway bypass) has demonstrated
sufficient efficacy to warrant Food and Drug Administration
approval at this time. Coupled with the reduction in priority
status for patients with chronic obstructive pulmonary disease
seeking a lung transplant, this potentially increases the
importance of LVRS for the management of selected
patients with severe chronic obstructive pulmonary disease.CONCLUSIONS
The current analysis of data obtained by the NETT im-
proves our ability to understand and clarify the current role
of LVRS. This analysis confirms that the NETT hypothesis
was indeed correct and that patients with heterogeneously
distributed upper lobe predominant emphysema achieved
significant benefit in terms of survival and functional im-
provement. We also conclude that for patients with a homo-
geneous pattern of emphysematous destruction, bilateral
LVRS offers no survival advantage and produces much
less functional improvement than in the heterogeneous upper
lobe predominant group.
This analysis of the NETT results confirms, with remarkable
concordance, the previous report by Ciccone and associates3
of a 250 consecutive case series of bilateral LVRS. We suspect
that the similarity of results will contribute to the ongoing
debate as to the relative merits of case–controlled series versus
randomized clinical trials for surgical procedures.References
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Dr Rodney J. Landreneau (Pittsburgh, Pa). This is a very nice
rehashing of what we have known for many years about LVRS. I
can remember when Jim Luketich joined me at the University of
Pittsburgh back in 1995 from Memorial. He believed it was like
a laminar air flow coming into the intensive care unit because of
all the negative suction coming from the chest tubes in place for
our LVRS patients. That was back in 1995 or so, right, Jim? By
1998, however, we had come to recognize that we were operating
on a lot of people erroneously, and then the NETT trial began.
If you look at the work of Dr Cooper’s group, who is leading us
out of Washington University, Larry Kaiser’s work at the University
of Pennsylvania, Mike Mack in Dallas, our work at the University of
Pittsburgh, Dan Miller at Louisville at that time, and Dr Weder in
Europe, we all had come to this conclusion by 1998 that this is the
group of people we should be operating on. Again, we were led
by Dr Cooper’s group, and I re-emphasize their article from 2002.
I think that what has occurred is really concerning, as I hope Dr
Cooper will re-reiterate. The trend of publications off the NETT
trial was unfortunate and has basically resulted in the death or
near death of LVRS for a number of patients who could have
benefited over the past 6 to 7 years. To me, it is the abomination
of health care at its finest through government intervention, and I
think that we need to guard against subsequent forays like this in
the future. Although we certainly need to avoid unnecessary sur-
gery and to economize our use of the health-care dollar, I think
that this is just a case in point on how to kill an advantageous inter-
vention for a select group of patients. I look forward to hearing Dr
Cooper’s comments.
Dr Cooper. Rod, thank you very much.
As I think you indicated, the point of this presentation is not to
criticize the NETT trial. It is to try to extract from it finally, and for
the first time ever, exactly what it set out to do. Who are the most
appropriate patients? There was a reason for that hypothesis,
Rod, and that was based on what you and I and others had done,
and the hypothesis was based correctly on the experience to date.
However, the hypothesis specifically said upper lobe predominant,
with a heterogeneous pattern. The NETT trial developed 2 separate
criteria for the patterns of emphysema. One defined homogeneous
and heterogeneous and the other defined predominance—2 totally
different criteria. But the hypothesis said that both have to be pres-
ent: predominance, that is, the upper lobe should be worse than the
rest of the zones, and also heterogeneous, as defined by the severity
grade developed by the NETT trial. Each of the 3 lung zones wasery c September 2010
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Sgraded in terms of severity on a scale of 0 to 5. For the upper lung
zone to be defined as heterogeneous, it had to be at least 2 severity
grades worse than the other zones on the same side. The problem
was that when they reported the data, they contaminated the data,
so that their second publication was only based on predominance,
and many of the upper lobe predominant patients had homogeneous
distribution by their definition, and they mixed homogeneous and
heterogeneous patients together when reporting the data. It was
only because there was a hypothesis and because they specifically
outlined how to define upper lobe predominance and heterogeneity
that we can present this information and not be accused of post hoc
examination of the data. That was probably the most serious charge
against the final NETT report, that they diced and sliced the data
retrospectively. Therefore, I appreciate the comment. Yes, there
may be other patients who require individual judgment, but the
NETT trial showed in a randomized fashion that if the right patients
are selected, the right result is achieved. And I think it is astonishing
that a multicenter trial, comprising 17 centers, was able to accom-
plish exactly, identically the same results that we obtained with our
original single-center report. That usually does not happen. Multi-
center trials usually do not achieve the same results. They did. They
did it beautifully. They achieved exactly the same results. The prob-
lem was that the manner in which it was presented was very, very
confusing and confused the surgeons, the referring physicians, and
the patients. I guess the message is that if the right patients are
chosed, the right results will be achieved.
Dr Robert J. Cerfolio (Birmingham, Ala). I have a quick ques-
tion for you, Joel. We all know what has happened. The pulmonol-
ogists have sort of pulled the plug on LVRS. I do 1 or 2 a year. The
question now is with the new Spiration valves (Spiration, Inc, Red-
mond, Wash) or the other endobronchial valves. Is that going to in-
crease the number of people coming from LVRS, and if it does,
who do you think should get the valve, endobronchial therapy,
and who should get LVRS, and why?
Dr Cooper. Well, isn’t it interesting that the pulmonologists
who pooh-poohed LVRS nonetheless got the message that if you
reduce overinflation in emphysema patients, you transform their
lives to the point that they got interested in interventional proce-
dures. But, as you may or may not know, one valve company’s trial
was not approved. They are out of business. The second valve com-
pany’s preliminary data showed no benefit, and I have little doubt
that their pivotal trial will show no benefit. The third company,
which developed the gluing technique, I believe is no longer oper-
ational. The only thing that is still standing, and here I have a con-
flict, is the airway bypass, which was really not designed for
patients with heterogeneous distribution but was designed for those
patients with homogeneous distribution. Ideally, the fact that there
does not appear to be a bronchoscopically effective alternative and
the fact that the NETT trial shows that if you focus on the right
patients, you get excellent results, will rekindle interest in LVRS.
I would also like to note that the NETT report retrospectively
broke up the upper lobe predominant patients into 2 subgroups
based on the preoperative exercise capacity defined as either high
or low exercise capacity. When you now look at the appropriate up-
per lobe predominant patients, namely, those who meet the criteria
of upper lobe predominant and heterogeneous, then the outcome
after LVRS is exactly the same whether or not the patient had
a high or low exercise capacity. The message is that the mostThe Journal of Thoracic and Caappropriate patients for LVRS are those who have an upper
lobe predominant, heterogeneous distribution pattern of emphy-
sema. I believe that it is necessary to promulgate the NETT data
in a transparent fashion and to eliminate what I like to call the toxic
data included in their analysis, namely, the inclusion of both het-
erogeneous and homogeneous distribution in what was called their
upper lobe predominant patients. This will highlight the true value
of the NETT study and lead to a resurgence of appropriate use of
LVRS.
Dr Cerfolio. That was a circuitous answer. I think the valves do
work. So my question is, in what patient who comes to you would
you put the endobronchial valve in and to whom would you recom-
mend LVRS and why?
Dr Cooper. You are right. First of all, the question is, will they
be allowed to sell any valves? One company is out. Maybe they
will. I have often said to a patient, ‘‘If I could only wish away
your upper lobes, I know you would be better. You would have
less hyperinflation. Your work at breathing would be better. I can’t
wish it away. I have to subject you to an operation. You’ve got
cardiac issues. You’ve got vascular issues. I don’t think it’s worth
the risk in your case.’’ That is the patient, in my opinion, who
might be considered for the valves if they are approved. That is
the group of patients for whom I would like to have an alternative
to LVRS.
Dr Walter Weder (Zurich, Switzerland). You write in your ab-
stract that a lot of data are missing in the medical group of the
NETT. Could you elucidate this?
Dr Cooper. I had 3 slides. Flip through those slides.
Dr Weder. Were these data relevant or irrelevant?
Dr Cooper. Dr Weder, I was very surprised to see how much
data were missing, so much so that we were unable to carry out
our analysis after the third year. It turns out that although the
NETT trial was 5 years, they stopped collecting data (and maybe
that was built into it) after 2 to 3 years. But, Walter, there were 2
primary end points. One is survival. Of course they had death re-
cords. That’s immaculate. They clearly have 100% data there.
The other was workload. This slide says pulmonary function tests
and functional data. Functional data was the maximum workload.
As you can see, functional data are missing on 30% of the patients
who are alive at least 1 year after randomization, and by 3 years
more than 35% of patients are missing functional data. When I
showed this to a statistician, he pointed out that not only does
the NETT trial validate our previously reported data, but in fact
our data validate the NETT trial data because we had less than
10% missing data at every time point to 5 years, and since we
had the same apparent results as the NETT trial, it means that
the missing data in the NETT trial were probably not critical. Spe-
cifically, it probably means that the missing data did not selectively
represent patients with a bad result; therefore, they did not neces-
sarily bias the outcome. Nonetheless, it was a surprise to find
out how much missing data there was in this highly funded,
well-organized trial.
Dr David M. Follette (Sacramento, Calif). Joel, I want to com-
pliment you, and I would like to have you make a comment on an-
other point. One of the great contributions I found from your work
is that it has greatly expanded my ability to operate on patients with
lung cancer. As you well know, there is a subgroup of patients with
cancer who are said to be inoperable because of poor pulmonaryrdiovascular Surgery c Volume 140, Number 3 571
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Sfunction. Because of your work, which was nicely summarized to-
day, I have used similar criteria to evaluate these cancer patients. In
those patients with heterogeneous disease with isolated lung can-
cers in the poorly perfused areas, I have performed resection of
the area. These patients have not only had great results with respect
to their cancer but have also had remarkable improvement in their
pulmonary function and exercise capacity. Dr Cooper, have you
looked at this subgroup of patients with a diagnosis of severe em-
physema and lung cancer?
Dr Cooper. We have. We actually had an initial report of our
first 20 patients—FEV1s less than 30%, all oxygen-dependent—
who underwent an anatomic lobectomy with or without additional
resections for volume reduction purposes. I think there was 1 death
and an excellent survival curve.
I believe we have obtained 3 benefits from volume reduction sur-
gery other than the benefit for the LVRS patients themselves: (1)572 The Journal of Thoracic and Cardiovascular Surgimproved anesthetic and pain management with high-risk patients
undergoing lung cancer, (2) the benefit of exercise rehabilitation
in patients with emphysema, and (3) the recognition that if the can-
cer is in the right place, a simple lobectomy or lobectomy plus some
other volume reduction not only gets rid of the cancer but also gives
significant improvement in lung function. In our series there was an
average of 38% improvement in the first second vital capacity in the
lobectomy patients whose preoperative FEV1 was less than 30%,
who were oxygen-dependent, and who were not candidates for
lobectomy for their cancer, based solely on their risk factors.
One of the old-time surgeons told me about a patient who had
demanded a lobectomy for his cancer. It was an upper lobe cancer,
and the patient had severe emphysema and was a very high risk.
The surgeon said, ‘‘I went ahead and did it, and I got rid of the can-
cer and he breathed much better.’’ If he had told us that years ago,
we would have started LVRS earlier.ery c September 2010
